June 03, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
‘Critically important’: Upfront sacituzumab govitecan combo benefits breast cancer subset
CHICAGO — New findings from the randomized phase 3 ASCENT-04 trial reinforce prior research that first-line sacituzumab govitecan plus pembrolizumab should be “standard of care” for PD-L1-positive metastatic triple-negative breast cancer.The data, presented at ASCO Annual Meeting, showed that patients treated upfront with sacituzumab govitecan (Trodelvy, Gilead Sciences) plus
1,499 words~7 min read
